GLP-1 Weight-Loss Drugs Are Reshaping Health Care

More Americans than ever are taking GLP-1 medications for weight loss. The numbers are hard to ignore. A new Gallup survey found that 15% of U.S. adults have used one of these drugs at some point for weight loss. Right now, 11% are actively taking one.

That’s up from just 3% in 2024. In other words, usage has nearly quadrupled in two years. This jump is reshaping doctor visits, prescribing habits, and even employee benefits packages.

Gallup polled more than 5,000 adults between late May and early June. Researchers point to two main drivers. First, prices have come down. Second, telehealth has made it much easier to get prescriptions. What once required a specialist referral can now happen through an app.

There’s a bigger public health story here, too. The national obesity rate has dropped from 39.9% in 2022 to 36.4% today. Dan Witters, who leads Gallup’s National Health and Well-Being Index, credits GLP-1s for part of that decline. He also notes that diabetes rates have leveled off after years of steady increases.

Doctors are seeing a shift in who asks for these medications. Kim Boyd, chief medical officer at Weight Watchers, explains that doctors used to frame weight as a willpower problem. Now, most clinicians treat it as a chronic condition tied to genetics, hormones, and environment. This shift has opened treatment to patients with lower BMIs and common conditions like high blood pressure and high cholesterol, not just those in the highest weight categories.

Still, Boyd cautions against reading too much into rising usage. More people talking about GLP-1s doesn’t mean everyone who needs them is getting them. Even with usage nearly quadrupling since 2024, only a small share of eligible patients receive care. CDC data puts the obesity rate closer to 40%, based on standard BMI measurements. It puts the overweight-or-obese share at 72%. Clearly, access still lags far behind need.

Employers now face a real cost question. Nearly all large companies cover GLP-1s for diabetes. Yet only 67% cover them specifically for weight management, according to SHRM research. Lisa Stevens, chief people officer at Aon, argues companies shouldn’t treat this as a simple yes-or-no decision. Instead, she says, the best outcomes happen when coverage comes paired with real support that keeps employees engaged in treatment over time.

There’s also a financial case for that investment. Scott Honken of Weight Watchers cites research showing that a 5% weight loss can cut annual health care costs by roughly $670 per person. A 25% loss pushes that savings past $2,000. Consequently, he frames GLP-1 coverage less as an expense and more as an investment in a chronic disease that also affects a company’s bottom line.

The workplace impact goes beyond dollars, too. In a Weight Watchers study of people enrolled in its clinical program, participants reported a 46% improvement in work-related quality of life. According to Honken, that kind of shift tends to ripple outward. It shows up as better engagement, higher job satisfaction, and fewer sick days.

The medications themselves keep evolving. What started as injectables now comes in pill form as well. So far, the FDA has approved nine GLP-1 and dual GLP-1/GIP medications. Wegovy, a semaglutide, received approval for weight loss back in 2021. Zepbound, a tirzepatide, followed in 2023.

Public awareness has caught up with the trend. Today, 91% of Americans know these drugs treat weight loss. However, not everyone chooses a brand-name version. About 19% of users take compounded formulations instead. These versions lack FDA approval and carry acknowledged risks around quality and dosing consistency. Even so, many people switch to them simply because they cost less. Roughly a third of compounded users say they made that switch from a brand-name drug.

Brand names still dominate the market overall. Sixty-eight percent of survey respondents said they take Ozempic or Wegovy rather than a compounded alternative. Interestingly, compounded users reported slightly higher satisfaction. Thirty-nine percent called their medication “extremely effective,” compared to 32% of brand-name users.

The reported benefits extend beyond the scale, too. Stevens notes that GLP-1s have shown links to fewer major cardiovascular events and lower hospitalization rates. She has also observed improvements across several chronic conditions, and even in mental health outcomes, though she frames these as emerging patterns worth watching, not settled conclusions.

As access continues to expand, the conversation is shifting. The question used to be how people get these drugs. Now it centers on how patients, and the systems supporting them, keep the results going long term.